The company closed its plan on May 14, 2024.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
41.9 CNY | -0.38% |
|
-0.59% | -7.36% |
06-05 | Hengrui Pharma Units Get China Nod for Clinical Trial of Tumor Drug | MT |
05-30 | Hengrui Pharmaceuticals Gets Nod to Trial Vitiligo Drug | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.36% | 36.72B | |
+50.70% | 791B | |
+41.46% | 630B | |
+18.77% | 328B | |
+8.79% | 298B | |
+17.68% | 246B | |
+0.20% | 225B | |
+10.22% | 218B | |
+3.68% | 160B | |
-4.38% | 156B |
- Stock Market
- Equities
- 600276 Stock
- News Jiangsu Hengrui Medicine Co., Ltd.
- Jiangsu Hengrui Medicine Co., Ltd.'s Equity Buyback announced on May 15, 2023, has closed with 14,351,878 shares, representing 0.22% for CNY 634.67 million.